STERIS (NYSE:STE) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

STERIS (NYSE:STE) released its quarterly earnings results on Monday. The medical equipment provider reported $2.83 earnings per share for the quarter, missing the consensus estimate of $2.86 by ($0.03), FiscalAI reports. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same period in the previous year, the business posted $2.74 earnings per share. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. STERIS updated its FY 2027 guidance to 11.100-11.300 EPS.

STERIS Price Performance

Shares of NYSE:STE opened at $203.98 on Tuesday. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $20.00 billion, a PE ratio of 28.71 and a beta of 0.95. The firm has a 50 day moving average of $222.37 and a 200-day moving average of $243.74. STERIS has a 12 month low of $195.14 and a 12 month high of $269.44.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be given a $0.63 dividend. The ex-dividend date is Monday, June 8th. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. STERIS’s payout ratio is presently 35.15%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on STE. Weiss Ratings cut STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, April 16th. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.20.

Trending Headlines about STERIS

Here are the key news stories impacting STERIS this week:

• Positive Sentiment: STERIS lifted FY2027 EPS guidance to $11.10-$11.30, above the consensus estimate, signaling confidence in future earnings growth. Reuters article
• Positive Sentiment: Revenue rose 7% year over year in fiscal Q4, showing the core medical equipment and sterilization business is still expanding. GlobeNewswire article
• Neutral Sentiment: Fourth-quarter EPS came in at $2.83 versus expectations of about $2.86, and revenue of $1.59 billion was slightly below estimates, a modest miss that tempers the upbeat outlook. Zacks article
• Neutral Sentiment: Management’s guidance for FY2027 revenue also came in roughly in line to slightly above expectations, reinforcing a steady but not dramatic growth profile. Yahoo Finance article
• Negative Sentiment: Recent insider activity has been mostly sales with no reported open-market purchases in the last six months, which may raise some caution among investors. Quiver Quantitative article

Insider Buying and Selling

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the sale, the director directly owned 705 shares in the company, valued at $167,233.05. This represents a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.07% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Walleye Trading LLC bought a new position in shares of STERIS in the 4th quarter valued at $274,000. Voleon Capital Management LP acquired a new position in shares of STERIS in the 2nd quarter worth approximately $263,000. Sherbrooke Park Advisers LLC bought a new stake in STERIS during the third quarter valued at $240,000. Elevation Point Wealth Partners LLC acquired a new stake in STERIS during the fourth quarter worth approximately $223,000. Finally, Compound Planning Inc. acquired a new stake in shares of STERIS during the 4th quarter worth approximately $220,000. Institutional investors own 94.69% of the company’s stock.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.